Heart failure in blacks: Etiologic and epidemiologic differences

被引：14

作者：

Yancy C.W. ^{[1
]}

机构：

[1] Heart Failure/Cardiac Transplantation, University of Texas Southwestern Medical School, Dallas, TX 75390

来源：

Current Cardiology Reports | 2001年 / 3卷 / 3期

关键词：

Heart Failure; Natriuretic Peptide; Carvedilol; Black Patient; Hypertensive Heart Disease;

D O I：

10.1007/s11886-001-0022-0

中图分类号：

学科分类号：

摘要：

Heart failure in black Americans has become a cardiovascular conundrum of increasing clinical significance. Over 60% of black patients with heart failure have an antecedent history of hypertension as a putative cause of left ventricular (LV) dysfunction, whereas only 30% have coronary artery disease as the suspected cause of LV dysfunction. Once affected with heart failure, the natural history of the disease becomes worrisome: LV dysfunction is more advanced, the severity of the disease is worse, the hospitalization rate is higher, and the mortality rate is at least 30% higher than that of white Americans. When treated in a conventional manner, available data have been inconsistent, and reliable drug efficacy has not been demonstrated. These differences do not appear to be due to socioeconomic factors. It is quite possible that unique pertubations in the neurohormonal environment may explain differences in the natural history of heart failure in blacks and yield new targets of therapy. © 2001 by Current Science Inc.

引用

页码：191 / 197

页数：6

共 27 条

[1]

Morbidity and Mortality: 1996 Chartbook on Cardiovascular, Lung, and Blood Diseases, (1996)

[2]

Cohn J.N., Results Reported at the 73rd Scientific Sessions of the American Heart Association, (2000)

[3]

Yancy C.W., Heart failure in African Americans: A cardiovascular enigma, J Card Fail, 6, pp. 183-186, (2000)

[4]

Dries D.L., Exner D.V., Gerch B.J., Et al., Racial differences in the outcome of left ventricular dysfunction, N Engl J Med, 340, pp. 609-616, (1999)

[5]

Carson P., Ziesche S., Johnson G., Cohn J.N., Racial differences in response to therapy for heart failure: Analysis of the vasodilator-heart failure trials, J Card Fail, 5, pp. 179-187, (1999)

[6]

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure, N Engl J Med, 325, pp. 293-302, (1991)

[7]

Packer M., Bristow M.R., Cohn J.N., Et al., The effect of carvedilol on morbidity and mortality in patients with chronic heart failure, N Engl J Med, 334, pp. 1349-1355, (1996)

[8]

Yancy C.W., Fowler M.B., Colucci W.S., Et al., Response of black heart failure patients to carvedilol [abstract], J Am Coll Cardiol, 29, (1997)

[9]

Domanski M.J., Eichhorn E.J., BEST (Beta-blockers Evaluation Survival Trial): Results Reported at the 72nd Scientific Sessions American Heart Association, (1999)

[10]

MERIT-HF Study Group: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in0020Congestive Heart Failure (MERIT-HF), Lancet, 353, pp. 2001-2007, (1999)

← 1 2 3 →